LONDON: 4basebio PLC (AIM: 4BB), the Cambridge based life sciences group focused on the development of synthetic DNA and non-viral vectors for use in the field of cell and gene therapies and vaccines, announced its collaboration with University of Alabama (“UA”) and Teesside University (“TU”) in a research project aimed at developing an effective treatment…
Tag: 4basebio PLC
4basebio PLC signs Joint Development Agreement with Heqet Therapeutics
LONDON: 4basebio PLC (AIM: 4BB), the life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA and mRNA vaccines, announced a Joint Development Agreement with Heqet Therapeutics S.r.l. This agreement is focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration…